METTL1 and intrahepatic cholangiocarcinoma: In intrahepatic cholangiocarcinoma (ICC), co-repressing METTL1 and its downstream chemokine pathway inhibited recruitment of myeloid-derived suppressor cells (MDSCs) and improved anti-PD-1 efficacy [227].